Comparing Proton Pump Inhibitors and Histamine Antagonists with Chemotherapy for Lymphoma
Comparative Clinical and Biochemical Study Evaluating the Effect of Proton Pump I Nhibitors Versus Histamine 2 Receptor Antagonists as an Adjuvant With Chemotherapy in Patients With Non-hodgkin Lymphoma.
This study is testing whether adding either a stomach acid reducer or a different type of medication to standard chemotherapy helps people with Non-Hodgkin Lymphoma do better in their treatment.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Cairo) |
| Trial ID | NCT03647072 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of Proton Pump Inhibitors (PPIs) versus histamine 2 receptor antagonists as adjuvants to chemotherapy in patients with Non-Hodgkin Lymphoma. It aims to determine which of these medications enhances the efficacy of the standard chemotherapy regimen (CHOP). The study will involve a comparative clinical and biochemical analysis to assess treatment outcomes. Participants will receive either standard chemotherapy alone or in combination with one of the two adjuvant medications.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with DLBCL Lymphoma who do not have any comorbid diseases.
Not a fit: Patients who are pregnant, have peptic ulcers, severe cardiac disease, or osteoporosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve treatment outcomes for patients with Non-Hodgkin Lymphoma by identifying the most effective adjuvant therapy.
How similar studies have performed: Other studies have explored the use of adjuvant therapies in chemotherapy, but this specific comparison of PPIs and histamine antagonists is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * DLBCL Lymphoma subtype --No comorbid disease Exclusion Criteria: * Pregnancy * Peptic ulcer * Severe cardiac disease * Osteoporosis
Where this trial is running
Cairo
- Sherief Abd-Elsalam — Cairo, Egypt (Recruiting)
Study contacts
- Principal investigator: Sahar K Hegazy, Prof — Clinical pharmacy Department- Tanta University
- Study coordinator: Sherief Abd-Elsalam, MD
- Email: sheriefabdelsalam@yahoo.com
- Phone: 00201147773440
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.